- Home
- LENZ vs RDIB Comparison
LENZ vs RDIB Comparison
Compare LENZ & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LENZ | RDIB |
|---|---|---|
| Founded | 2019 | 1937 |
| Country | United States | United States |
| Employees | N/A | 2025 |
| Industry | Medicinal Chemicals and Botanical Products | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.4M | 224.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LENZ | RDIB |
|---|---|---|
| Price | $7.79 | $9.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $44.00 | N/A |
| AVG Volume (30 Days) | ★ 734.8K | 2.3K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,088,000.00 | N/A |
| Revenue This Year | $50.42 | $16.25 |
| Revenue Next Year | $197.16 | $4.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.25 | $8.50 |
| 52 Week High | $50.19 | $17.40 |
Technical Indicators
Market Signals| Indicator | LENZ | RDIB |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 45.94 |
| Support Level | N/A | $9.27 |
| Resistance Level | $10.34 | $10.70 |
| Average True Range (ATR) | 0.64 | 0.23 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 28.21 | 44.30 |
Price Performance
Historical ComparisonAbout LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.